226 related articles for article (PubMed ID: 34115379)
1. Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms.
Brada LJH; Walma MS; Daamen LA; van Roessel S; van Dam RM; de Hingh IH; Liem MLS; de Meijer VE; Patijn GA; Festen S; Stommel MWJ; Bosscha K; Polée MB; Yung Nio C; Wessels FJ; de Vries JJJ; van Lienden KP; Bruijnen RC; Los M; Mohammad NH; Wilmink HW; Busch OR; Besselink MG; Quintus Molenaar I; van Santvoort HC;
J Surg Oncol; 2021 Sep; 124(4):589-597. PubMed ID: 34115379
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113).
Hartlapp I; Valta-Seufzer D; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens UM; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Anger F; Germer CT; Stang A; Kimmel B; Heinemann V; Kunzmann V;
ESMO Open; 2022 Aug; 7(4):100552. PubMed ID: 35970013
[TBL] [Abstract][Full Text] [Related]
3. Impact of a non-therapeutic laparotomy in patients with locally advanced pancreatic cancer treated with induction (m)FOLFIRINOX: Trans-Atlantic Pancreatic Surgery (TAPS) Consortium study.
Theijse RT; Stoop TF; Janssen QP; Prakash LR; Katz MHG; Doppenberg D; Tzeng CD; Wei AC; Zureikat AH; Groot Koerkamp B; Besselink MG
Br J Surg; 2024 Mar; 111(3):. PubMed ID: 38456678
[TBL] [Abstract][Full Text] [Related]
4. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma.
Yoo C; Hwang I; Song TJ; Lee SS; Jeong JH; Park DH; Seo DW; Lee SK; Kim MH; Byun JH; Park JH; Hwang DW; Song KB; Lee JH; Lee W; Chang HM; Kim KP; Kim SC; Ryoo BY
Ther Adv Med Oncol; 2020; 12():1758835920953294. PubMed ID: 32983266
[TBL] [Abstract][Full Text] [Related]
5. Minimum and Optimal CA19-9 Response After Two Months Induction Chemotherapy in Patients With Locally Advanced Pancreatic Cancer: A Nationwide Multicenter Study.
Seelen LWF; Doppenberg D; Stoop TF; Nagelhout A; Brada LJH; Bosscha K; Busch OR; Cirkel GA; den Dulk M; Daams F; van Dieren S; van Eijck CHJ; Festen S; Groot Koerkamp B; Haj Mohammad N; de Hingh IHJT; Lips DJ; Los M; de Meijer VE; Patijn GA; Polée MB; Stommel MWJ; Walma MS; de Wilde RF; Wilmink JW; Molenaar IQ; van Santvoort HC; Besselink MG;
Ann Surg; 2024 May; 279(5):832-841. PubMed ID: 37477009
[TBL] [Abstract][Full Text] [Related]
6. Duration of therapy for locally advanced pancreatic cancer: Does it matter?
Tuli R; David J; Lobaugh S; Zhang Z; O'Reilly EM
Cancer Med; 2020 Jul; 9(13):4572-4580. PubMed ID: 32368871
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Short- and Long-Term Outcomes After Resection in Patients with Locally Advanced versus (Borderline) Resectable Pancreatic Cancer.
Brada LJH; Schouten TJ; Daamen LA; Seelen LWF; Walma MS; van Dam R; de Hingh IH; Liem MSL; de Meijer VE; Patijn GA; Festen S; Stommel MWJ; Bosscha K; Besselink MG; van Santvoort HC; Molenaar IQ;
Ann Surg; 2024 Apr; ():. PubMed ID: 38557955
[TBL] [Abstract][Full Text] [Related]
8. Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only: Multicenter Propensity Score-matched Analysis.
Brada LJH; Daamen LA; Magermans LG; Walma MS; Latifi D; van Dam RM; de Hingh IH; Liem MSL; de Meijer VE; Patijn GA; Festen S; Stommel MWJ; Bosscha K; Polée MB; Nio YC; Wessels FJ; de Vries JJJ; van Lienden KP; Bruijnen RC; Busch OR; Koerkamp BG; van Eijck C; Molenaar QI; Wilmink HJW; van Santvoort HC; Besselink MG;
Ann Surg; 2021 Nov; 274(5):729-735. PubMed ID: 34334641
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer: A systematic review and meta-analysis.
Zhang H; You J; Liu W; Chen D; Zhang S; Wang X
Medicine (Baltimore); 2021 Jul; 100(30):e26714. PubMed ID: 34397704
[TBL] [Abstract][Full Text] [Related]
10. Gastric cancer with positive peritoneal cytology: survival benefit after induction chemotherapy and conversion to negative peritoneal cytology.
Valletti M; Eshmuminov D; Gnecco N; Gutschow CA; Schneider PM; Lehmann K
World J Surg Oncol; 2021 Aug; 19(1):245. PubMed ID: 34404403
[TBL] [Abstract][Full Text] [Related]
11. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
[TBL] [Abstract][Full Text] [Related]
12. An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer.
Kiss D; Machackova T; Souckova K; Fabian P; Krepelkova I; Svoboda M; Kiss I
In Vivo; 2021; 35(5):2809-2814. PubMed ID: 34410972
[TBL] [Abstract][Full Text] [Related]
13. Ferritin: A Multifunctional Nanoplatform for Biological Detection, Imaging Diagnosis, and Drug Delivery.
Song N; Zhang J; Zhai J; Hong J; Yuan C; Liang M
Acc Chem Res; 2021 Sep; 54(17):3313-3325. PubMed ID: 34415728
[TBL] [Abstract][Full Text] [Related]
14. Dysgonomonas capnocytophagoides Bacteremia in a Patient With Stage IV Colon Adenocarcinoma.
Schall SE; Blyth DM; McCarthy SL
Cureus; 2021 Jul; 13(7):e16381. PubMed ID: 34408935
[No Abstract] [Full Text] [Related]
15. Extensive drug-resistance in strains of
Iqbal Z; Mumtaz MZ; Malik A
J Taibah Univ Med Sci; 2021 Aug; 16(4):565-574. PubMed ID: 34408614
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey.
Orsi G; Di Marco M; Cavaliere A; Niger M; Bozzarelli S; Giordano G; Noventa S; Rapposelli IG; Garajova I; Tortora G; Rodriquenz MG; Bittoni A; Penzo E; De Lorenzo S; Peretti U; Paratore C; Bernardini I; Mosconi S; Spallanzani A; Macchini M; Tamburini E; Bencardino K; Giommoni E; Scartozzi M; Forti L; Valente MM; Militello AM; Cascinu S; Milella M; Reni M
ESMO Open; 2021 Oct; 6(5):100238. PubMed ID: 34392104
[TBL] [Abstract][Full Text] [Related]
17. Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Janssen QP; van Dam JL; Kivits IG; Besselink MG; van Eijck CHJ; Homs MYV; Nuyttens JJME; Qi H; van Santvoort HJ; Wei AC; de Wilde RF; Wilmink JW; van Tienhoven G; Groot Koerkamp B
Ann Surg Oncol; 2021 Dec; 28(13):8297-8308. PubMed ID: 34142290
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Routinely used Analgesics in Management of Pulpal Pain Postoperatively a Clinical Study.
Thota L; Bansal R; Thota G; Chikkanna MK; Shanab H; Kumari VV
J Pharm Bioallied Sci; 2021 Jun; 13(Suppl 1):S684-S687. PubMed ID: 34447181
[TBL] [Abstract][Full Text] [Related]
19. Antibiotics' susceptibility patterns of bacterial isolates causing lower respiratory tract infections in ICU patients at referral hospitals in Namibia.
Simeon P; Godman B; Kalemeera F
Hosp Pract (1995); 2021 Dec; 49(5):356-363. PubMed ID: 34436942
[TBL] [Abstract][Full Text] [Related]
20. Proton pump inhibitors may contribute to progression or development of chronic obstructive pulmonary disease-A sequence symmetry analysis approach.
Janetzki JL; Sykes MJ; Ward MB; Pratt NL
J Clin Pharm Ther; 2021 Dec; 46(6):1687-1694. PubMed ID: 34431531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
